Ken Griffin
ARTL icon

Ken Griffin’s Artelo Biosciences ARTL Stock Holding History

Ken Griffin’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,261
Closed -$19.9K – 12444
2025
Q1 		$19.9K Buy
+1,261
New +$25.3K ﹤0.01% 13146
2022
Q1 		– Sell
-291
Closed -$41K – 13526
2021
Q4 		$41K Buy
291
+188
+183% +$37.1K ﹤0.01% 13352
2021
Q3 		$22K Sell
103
-172
-63% -$43.7K ﹤0.01% 13632
2021
Q2 		$88K Sell
275
-395
-59% -$135K ﹤0.01% 13016
2021
Q1 		$295K Buy
+670
New +$286K ﹤0.01% 10893

Other funds holding ARTL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ken Griffin's ARTL Position: Q2 2025 in Review

Ken Griffin sold out of Artelo Biosciences (ARTL) in Q2 2025, closing a stake of 1,261 shares — an estimated $19.9K sold.

Ken Griffin first reported a position in ARTL in Q1 2021 and held it in 5 quarters. The position peaked at $295K in Q1 2021. 6 funds tracked by Wall St. Rank hold ARTL as of Q2 2025.

  • Ken Griffin reported no remaining Artelo Biosciences position as of Q2 2025 after selling out during the quarter.
  • Ken Griffin sold 1,261 Artelo Biosciences shares in Q2 2025, an estimated $19.9K.
  • Ken Griffin first reported a position in Artelo Biosciences in Q1 2021 and held it in 5 quarters.
  • Ken Griffin's Artelo Biosciences position peaked at $295K in Q1 2021.
  • 6 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.